Akeso Enrolls First Patient In Phase 3 Cadonilimab Head-To-Head Gastric Cancer Trial

India, Sept. 28 -- Akeso, Inc. (9926.HK), a biopharmaceutical company, announced that it has enrolled the first patient in COMPASSION-37 (AK104-311), a phase 3 trial evaluating Cadonilimab as first-line treatment for patients with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

COMPASSION-37 is a global, multicenter phase 3 head-to-head trial evaluating cadonilimab in combination with chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for patients with HER2-negative, previously untreated, unresectable or metastatic G/GEJ adenocarcinoma.

Cadonilimab is a PD-1/CTLA-4 bispecific antibody developed by Akeso for cancer immunotherapy.

N...